The global androgenic alopecia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The growing prevalence of hair loss, technological advancements in alopecia treatment, and the rise in prevalence of chronic diseases that are associated with hair loss are some of the major factors driving the market. According to data published by the American Hair Loss Association, it was stated that over 95.0% of hair loss in men is caused due to androgenic alopecia. Similarly, data published by the International Society of Hair Restoration Surgery estimated that nearly 40.0% of men encounter some degree of hair loss by 35 years of age, 65.0% at 60 years, 70.0% at 80 years, and 80.0% at the age of 85. Thus, this factor is propelling the global androgenic alopecia drug market growth.

Apart from the general misconception that alopecia affects males, females too encounter this condition on a wide scale. According to the American Academy of Dermatology Association (AAD), about 50 million men and 30 million women were estimated to be affected by some form of alopecia in the US in 2018. According to data published by the Journal of Clinical and Diagnostic Research (JCDR), around 60% of the population has hair thinning problems and pattern hair loss is the most common form of hair loss in both males and females. Moreover, around 2.0% of the population all over the globe is at risk of developing androgenic alopecia in their lifetime, irrespective of gender. This, in turn, is driving the demand for androgenic alopecia drug market.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By End-User 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Allergan plc, Cipla Ltd., and Dr. Reddy's Laboratories, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Androgenic Alopecia Drug Market Report by Segment

By Type

• RK-023

• RCH-01

• Refagro

• SM-04554

• HYG-440

• Others

By End-User

• Clinic

• Hospital

• Homecare Settings

Global Androgenic Alopecia Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa